The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE , more than five years after both ...

Move marks shift after years of mRNA collaboration that produced COVID-19 vaccine.

BioNTech (BNTX) stock slips as Pfizer (PFE) plans to sell its remaining stake in the COVID-19 vaccine developer in a ...

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and BioNTech (NASDAQ:BNTX) announced that the Health Sciences Authority/HSA of ...

Children and adolescents had higher risks of vascular and inflammatory diseases after a first COVID diagnosis, as well as a ...

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...